182 related articles for article (PubMed ID: 9586648)
1. The Western Australian HIV Cohort Study, Perth, Australia.
Mallal SA
J Acquir Immune Defic Syndr Hum Retrovirol; 1998; 17 Suppl 1():S23-7. PubMed ID: 9586648
[TBL] [Abstract][Full Text] [Related]
2. HIV infection and AIDS.
Lloyd A
P N G Med J; 1996 Sep; 39(3):174-80. PubMed ID: 9795558
[TBL] [Abstract][Full Text] [Related]
3. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
4. Natural history of opportunistic disease in an HIV-infected urban clinical cohort.
Moore RD; Chaisson RE
Ann Intern Med; 1996 Apr; 124(7):633-42. PubMed ID: 8607591
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
7. Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections.
Williams PL; Currier JS; Swindells S
AIDS; 1999 Jun; 13(9):1035-44. PubMed ID: 10397533
[TBL] [Abstract][Full Text] [Related]
8. Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population-based cohort.
Longini IM; Clark WS; Karon JM
Am J Epidemiol; 1993 Jun; 137(11):1229-40. PubMed ID: 8100682
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis for opportunistic infections in an era of effective antiretroviral therapy.
Powderly WG
Clin Infect Dis; 2000 Aug; 31(2):597-601. PubMed ID: 10987727
[TBL] [Abstract][Full Text] [Related]
10. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
[TBL] [Abstract][Full Text] [Related]
11. Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996-1997.
Binquet C; Chêne G; Jacqmin-Gadda H; Journot V; Savès M; Lacoste D; Dabis F;
Am J Epidemiol; 2001 Feb; 153(4):386-93. PubMed ID: 11207157
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells.
French M; Keane N; McKinnon E; Phung S; Price P
HIV Med; 2007 Apr; 8(3):148-55. PubMed ID: 17461858
[TBL] [Abstract][Full Text] [Related]
13. HIV infection/acquired immunodeficiency syndrome at Siriraj Hospital, 2002: time for secondary prevention.
Anekthananon T; Ratanasuwan W; Techasathit W; Rongrungruang Y; Suwanagool S
J Med Assoc Thai; 2004 Feb; 87(2):173-9. PubMed ID: 15061301
[TBL] [Abstract][Full Text] [Related]
14. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.
D'Egidio GE; Kravcik S; Cooper CL; Cameron DW; Fergusson DA; Angel JB
AIDS; 2007 Aug; 21(13):1711-5. PubMed ID: 17690568
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
[TBL] [Abstract][Full Text] [Related]
17. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
18. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts.
Yazdanpanah Y; Chêne G; Losina E; Goldie SJ; Merchadou LD; Alfandari S; Seage GR; Sullivan L; Marimoutou C; Paltiel AD; Salamon R; Mouton Y; Freedberg KA
Int J Epidemiol; 2001 Aug; 30(4):864-71. PubMed ID: 11511618
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS.
El-Sadr WM; Burman WJ; Grant LB; Matts JP; Hafner R; Crane L; Zeh D; Gallagher B; Mannheimer SB; Martinez A; Gordin F
N Engl J Med; 2000 Apr; 342(15):1085-92. PubMed ID: 10766581
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons.
Crowe SM; Carlin JB; Stewart KI; Lucas CR; Hoy JF
J Acquir Immune Defic Syndr (1988); 1991; 4(8):770-6. PubMed ID: 1677419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
